Business Context and Reporting Period
Company: Senseonics Holdings, Inc. (SENS)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Senseonics is a medical technology company developing and commercializing the Eversense implantable continuous glucose monitoring (CGM) system. The company recently transitioned commercial responsibility for its products from its partner, Ascensia Diabetes Care Holdings AG, back to Senseonics. Effective January 1, 2026, Senseonics assumed full commercial control in the U.S. and is entitled to 100% of revenues from European territories (Italy, Germany, Spain, Sweden), with a full transition expected by mid-2026.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $35.3 million | $22.5 million | +$12.8 million (57% increase) |
| Gross Profit | $15.8 million | $0.5 million | +$15.2 million |
| Gross Margin | 44.7% | 2.4% | +42.3 percentage points |
| Operating Loss | $(68.3) million | $(74.8) million | Improvement of $6.5 million |
| Net Loss | $(69.1) million | $(78.6) million | Improvement of $9.5 million |
| Cash & Equivalents | $40.2 million | $74.6 million | Decrease of $34.4 million |
| Total Liquid Assets | $94.0 million | $74.6 million | Includes $53.8 million in short-term investments |
| Debt (Long-term) | $35.6 million | $34.7 million | Amended Loan and Security Agreement |
Note: Revenue growth was driven by U.S. consignment sales and demand for the 365-day Eversense product. Gross margin improvement was due to favorable product mix, lower fixed manufacturing costs, and the absence of one-time transition charges incurred in 2024.
Material Changes vs. Prior Period
- Commercial Transition: The most significant change is the termination of Ascensia's exclusive U.S. marketing rights and the shift to non-exclusive rights in select European territories. Senseonics now controls its own sales force and marketing strategy in the U.S.
- Product Launch: The Eversense 365 (1-year duration) was FDA approved in September 2024 and CE Mark approved in January 2026. December 2025 saw record patient shipments.
- Expense Structure: Selling, General, and Administrative (SG&A) expenses increased by $18.3 million (53%) to $52.5 million, primarily due to $11.3 million in direct-to-consumer marketing and costs associated with the commercial transition. Conversely, R&D expenses decreased by $9.5 million to $31.6 million following the completion of pivotal trials for Eversense 365.
- Debt Restructuring: The company amended its Loan and Security Agreement in September 2025, increasing the total facility commitment from $50.0 million to $100.0 million. The 2025 Convertible Notes were fully repaid in January 2025.
Guidance, Outlook, Risks, and Contingencies
Outlook and Guidance
The filing does not provide specific numerical financial guidance for 2026. Management expects to continue incurring operating losses as it invests in commercialization, R&D for next-generation products (Gemini and Freedom), and the transition of European operations. The company anticipates that revenue increases from the transition may not immediately offset the significant rise in operating expenses required to build internal commercial capabilities.
Going Concern Warning
Critical Risk: The company has concluded that substantial doubt exists regarding its ability to continue as a going concern for the twelve months following the issuance of the financial statements. Management projects it may not meet debt covenants as early as the third quarter of 2026 and will require additional liquidity to fund operations and the commercial transition.
Key Risks and Contingencies
- Liquidity: The company must secure additional capital through public/private financings, collaborations, or asset sales. Failure to do so could force a reduction in operations.
- Debt Covenants: The Amended Loan and Security Agreement includes minimum cash covenants and performance covenants (revenue targets) commencing January 1, 2026. Breach could trigger acceleration of debt.
- Commercial Execution: Success depends on the smooth transition of commercial operations from Ascensia, the ability to recruit and train a new sales force, and the expansion of the inserter network (Eon Care).
- Reimbursement: Revenue is heavily dependent on third-party payor coverage. While coverage has expanded (e.g., UnitedHealthcare, Medicare), some payors still deem the technology investigational.
- Legal Proceedings: The company is involved in patent litigation with Cellspin Soft, Inc. (stayed pending Inter Partes Review proceedings). The outcome is uncertain but could result in significant costs or injunctions.
Investor Verification Checklist
- Liquidity Runway: Verify the company's progress in securing additional financing to address the "substantial doubt" regarding going concern status and meet Q3 2026 debt covenants.
- Commercial Transition Metrics: Monitor the successful hiring and ramp-up of the new U.S. sales force and the execution of European asset purchase agreements (expected by March 31, 2026).
- Revenue Mix: Track the shift from distributor sales (Ascensia) to direct consignment and distributor sales to ensure the company captures the full revenue value previously shared with Ascensia.
- Reimbursement Status: Confirm the status of coverage policy transitions for Eversense 365 with major commercial payors and Medicare Administrative Contractors.
- Debt Covenant Compliance: Review upcoming quarterly reports for compliance with the minimum cash and revenue targets under the Amended Loan and Security Agreement.